Medesis Pharma S.A. (ALMDP.PA)
EUR 0.35
(0.0%)
EUR 0.35
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.84 Million EUR | -25.12% |
| 2022 | -3.05 Million EUR | -0.67% |
| 2021 | -3.04 Million EUR | -243.84% |
| 2020 | -894.97 Thousand EUR | -42.5% |
| 2019 | -622 Thousand EUR | 25.51% |
| 2018 | -835 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | -1.2 Million EUR | 0.0% |
| 2023 Q2 | -766.34 Thousand EUR | 0.0% |
| 2023 Q1 | -766.34 Thousand EUR | -13.13% |
| 2023 Q3 | -1.2 Million EUR | -56.63% |
| 2023 FY | - EUR | -25.12% |
| 2022 Q1 | -893.55 Thousand EUR | -1.91% |
| 2022 Q4 | -677.42 Thousand EUR | 0.0% |
| 2022 Q3 | -677.42 Thousand EUR | 24.19% |
| 2022 Q2 | -893.55 Thousand EUR | 0.0% |
| 2022 FY | - EUR | -0.67% |
| 2021 FY | - EUR | -243.84% |
| 2021 Q4 | -876.79 Thousand EUR | 0.0% |
| 2021 Q3 | -876.79 Thousand EUR | -34.27% |
| 2021 Q2 | -653.02 Thousand EUR | 0.0% |
| 2021 Q1 | -653.02 Thousand EUR | -196.1% |
| 2020 FY | - EUR | -42.5% |
| 2020 Q4 | -220.53 Thousand EUR | 0.0% |
| 2020 Q3 | -220.53 Thousand EUR | 2.82% |
| 2020 Q1 | -226.95 Thousand EUR | 0.0% |
| 2020 Q2 | -226.94 Thousand EUR | 0.0% |
| 2019 FY | - EUR | 25.51% |
| 2018 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.29 Million EUR | -16.866% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 97.114% |
| Adocia SA | -22.73 Million EUR | 83.086% |
| Aelis Farma SA | -6.34 Million EUR | 39.422% |
| Biophytis S.A. | -13.8 Million EUR | 72.147% |
| Advicenne S.A. | -6.24 Million EUR | 38.423% |
| genOway Société anonyme | 6.35 Million EUR | 160.542% |
| IntegraGen SA | -52.5 Thousand EUR | -7223.17% |
| Neovacs S.A. | -8.44 Million EUR | 54.496% |
| NFL Biosciences SA | -4.04 Million EUR | 5.048% |
| Plant Advanced Technologies SA | 72.53 Thousand EUR | 5401.095% |
| Quantum Genomics Société Anonyme | -2.87 Million EUR | -33.806% |
| Sensorion SA | -22.31 Million EUR | 82.769% |
| Theranexus Société Anonyme | -7.38 Million EUR | 47.952% |
| TME Pharma N.V. | -5.07 Million EUR | 24.194% |
| Valbiotis SA | -6.95 Million EUR | 44.718% |
| TheraVet SA | -517.33 Thousand EUR | -643.208% |
| Valerio Therapeutics Société anonyme | -18.91 Million EUR | 79.674% |
| DBV Technologies S.A. | -79.53 Million EUR | 95.166% |
| Genfit S.A. | -28.05 Million EUR | 86.293% |
| GeNeuro SA | -14.31 Million EUR | 73.146% |
| Innate Pharma S.A. | -7.57 Million EUR | 49.263% |
| Inventiva S.A. | -101.84 Million EUR | 96.225% |
| MaaT Pharma SA | -19.74 Million EUR | 80.522% |
| MedinCell S.A. | -20.04 Million EUR | 80.82% |
| Nanobiotix S.A. | -34.01 Million EUR | 88.698% |
| OSE Immunotherapeutics SA | -23.26 Million EUR | 83.474% |
| Poxel S.A. | -12.17 Million EUR | 68.43% |
| GenSight Biologics S.A. | -21.73 Million EUR | 82.306% |
| Transgene SA | -27.02 Million EUR | 85.772% |
| Valneva SE | -64.51 Million EUR | 94.041% |